Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Psoriasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dermatitis 1

Interventions

fludarabine phosphate 23Mycophenolic Acid 19Cyclophosphamide 19Whole-Body Irradiation 15Tacrolimus 11Peripheral Blood Stem Cell Transplantation 11fludarabine 10Cyclosporine 9Antilymphocyte Serum 9Rituximab 8Cyclosporins 8Busulfan 7Sirolimus 5Methotrexate 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4ibrutinib 3Melphalan 3Cord Blood Stem Cell Transplantation 3Allopurinol 3Stem Cell Transplantation 2Lenalidomide 2Hematopoietic Stem Cell Transplantation 2Epoetin Alfa 2Alemtuzumab 2treosulfan 1thymoglobulin 1tafasitamab 1sotrastaurin 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Prolymphocytic × sotrastaurin × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡